Galapagos NV (NASDAQ:GLPG) was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a report released on Friday, Marketbeat reports. The brokerage presently has a $101.00 price objective on the biotechnology company’s stock, up from their prior price objective of $83.00. Stifel Nicolaus’ price target points to a potential upside of 20.63% from the stock’s current price.

The analysts wrote, “Aurinia reported 2Q17 financial results in an after market close press release.””

A number of other equities analysts have also recently weighed in on GLPG. Cowen and Company reaffirmed a “buy” rating on shares of Galapagos NV in a report on Thursday. BidaskClub cut Galapagos NV from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Morgan Stanley reaffirmed an “overweight” rating and issued a $92.00 price target on shares of Galapagos NV in a report on Thursday. BTIG Research reaffirmed a “buy” rating and issued a $98.00 price target on shares of Galapagos NV in a report on Thursday, July 20th. Finally, Zacks Investment Research cut Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday, April 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $96.14.

Galapagos NV (NASDAQ:GLPG) traded up 3.29% on Friday, hitting $83.73. The stock had a trading volume of 353,470 shares. Galapagos NV has a 52-week low of $52.50 and a 52-week high of $94.88.

COPYRIGHT VIOLATION WARNING: “Galapagos NV (NASDAQ:GLPG) Upgraded at Stifel Nicolaus” was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/13/galapagos-nv-nasdaqglpg-upgraded-at-stifel-nicolaus.html.

Several institutional investors have recently made changes to their positions in GLPG. Tower Research Capital LLC TRC purchased a new position in shares of Galapagos NV during the first quarter worth approximately $161,000. Bank of Montreal Can boosted its position in shares of Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Galapagos NV during the second quarter worth approximately $166,000. New York State Common Retirement Fund purchased a new position in shares of Galapagos NV during the second quarter worth approximately $166,000. Finally, Pacad Investment Ltd. purchased a new position in shares of Galapagos NV during the second quarter worth approximately $168,000. 19.99% of the stock is owned by institutional investors and hedge funds.

Galapagos NV Company Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.